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Abstract
The crystal structure of the human immunodeficiency virus type 1 (HIV-1) neutralizing, murine Fab 83.1 in complex with an HIV-1
gp120 V3 peptide has been determined to 2.57 Å resolution. The conformation of the V3 loop peptide in complex with Fab 83.1 is very
similar to V3 conformations seen previously with two other neutralizing Fabs, 50.1 and 59.1. The repeated identification of this same V3
conformation in complex with three very different, neutralizing antibodies indicates that it is a highly preferred structure for V3 loops on
some strains of the HIV-1 virus.
© 2003 Elsevier Inc. All rights reserved.
Keywords: HIV-1; Neutralizing antibody; V3, X-ray crystallography
Introduction
The human immunodeficiency virus type 1 (HIV-1) virus
is a membrane-coated lentivirus whose outer surface is
embedded with spikes made up of the envelope glycopro-
teins gp120 and gp41. These two surface proteins are orig-
inally encoded by the single polypeptide chain gp160 and,
after proteolytic cleavage (McCune et al., 1988), stay non-
covalently associated on the viral surface as oligomeric,
probably trimeric, assemblies (Earl et al., 1990; Gelderblom
et al., 1987; Ozel et al., 1988; Pinter et al., 1989; Weiss, et
al., 1990). The gp41 protein contains a membrane-spanning
domain that anchors it to the viral membrane so that gp120
remains noncovalently associated around the membrane-
bound trimeric gp41. The gp120 protein is responsible for
binding to the major cellular receptor, CD4 (Dalgleish et al.,
1984; Klatzmann et al., 1984), as well as to coreceptors,
such as CCR5 (Alkhatib et al., 1996; Choe et al., 1996;
Deng et al., 1996; Doranz et al., 1996; Dragic et al., 1996)
or CXCR4 (Feng et al., 1996).
Sequence analysis of gp120 has revealed five variable
regions in the protein, termed V1–V5 (Starcich et al., 1986).
The third hypervariable region (V3) of gp120 consists of
approximately 40 residues (varying in length depending on
the viral isolate) with a conserved disulfide bridge (Cys
296–Cys 331; HXB2 numbering) at the base of the loop.
The V3 loop region is integral to many aspects of HIV-1
viral infectivity. Variation in the V3 sequence is linked with
changes in cell tropism (Cann et al., 1992; Chavda et al.,
1994; Chesebro et al., 1992, 1996; Harrowe and Cheng-
Mayer, 1995; Hwang et al., 1991; Mammano et al., 1995;
Stamatatos and Cheng-Mayer, 1993), the ability to induce
syncitia (Bhattacharyya et al., 1996; de Jong et al., 1992b;
Fouchier et al., 1992; Hogervorst et al., 1995; Milich et al.,
1997), the ability to be neutralized by soluble CD4 (Hwang
et al., 1992), and the progression from initial infection to
full-blown AIDS (Distler et al., 1995). These features of V3
can all be correlated with its role in the interaction of gp120
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with coreceptors CCR5 or CXCR4 (Cocchi et al., 1996;
Speck et al., 1997; Wang et al., 1998; Xiao et al., 1998). The
V3 loop has also been termed the “principal neutralizing
determinant” (Javaherian et al., 1989) because peptides and
protein fragments containing the V3 region were originally
described as having a high propensity to elicit neutralizing
antibodies (Goudsmit et al., 1988; Palker et al., 1988;
Rusche et al., 1988).
Early excitement about the possibility of creating an
effective vaccine based only on intact gp120 or smaller
fragments containing the V3 loop region has since abated.
Although these constructs can induce a strong immune
response toward V3, the antibodies generated, for the most
part, neutralize only laboratory-adapted isolates (TCLA)
(Mascola et al., 1994; Matthews, 1994) and are usually
specific for only a small number of different strains (Palker
et al., 1988). This puzzling phenomenon is most likely due
to differential exposure of V3 on different virus strains, and
at different stages of the viral entry process. Primary viral
isolates, which utilize the CCR5 coreceptor and are respon-
sible for most initial infections, are extremely resistant to
neutralization by the vast majority of antibodies, including
most directed against the V3 loop. Thus, the V3 loop may
be inaccessible in primary isolates, either due to masking by
carbohydrate or because of tertiary or quaternary interac-
tions with the gp120 oligomeric complex. As viruses adapt
to live in cell culture, or mutate in vivo in the progression
toward full-blown AIDS, their V3 regions change in se-
quence and acquire more positively charged residues (de
Jong et al., 1992a; Fouchier et al., 1992). The viruses then
become more amenable to neutralization, presumably be-
cause their V3 regions become more accessible for interac-
tion with antibodies, due either to local conformational
changes within or around V3 or to destabilization of the
gp120 oligomeric assembly.
The gp120 glycoprotein appears to adopt several differ-
ent conformational states, such as after the cleavage of
gp160 to gp120 and gp41 (McCune et al., 1988), after CD4
binding (Kang et al., 1993; McKeating et al., 1992; Myszka
et al., 2000; Sattentau and Moore, 1991; Sattentau et al.,
1993; Thali et al., 1993; Xiang et al., 2002), and after
interaction with coreceptor (Chan and Kim, 1998; Freed and
Martin, 1995; Wyatt and Sodroski, 1998). These conforma-
tional changes include variation in V3 shape or exposure
(Stamatatos and Cheng-Mayer, 1995), as shown by changes
in V3 reactivity with conformation-dependent antibodies.
Better understanding of the structural changes that can take
place in gp120 is essential to fully explain mechanisms of
receptor binding and membrane fusion.
To date, the only available crystal structures for gp120
are for deglycosylated core regions of gp120 from HXB2
and YU2 isolates, where 52 N- and 19 C-terminal, 67
V1/V2, and 32 V3 loop residues (298–229) have been
deleted (Kwong et al., 1998, 2000). While these ground-
breaking structures of monomeric gp120 core regions have
provided a plethora of extraordinarily valuable structural
information, many unanswered questions remain about the
range of conformational states that gp120 can adopt. By
studying the conformations of V3 that are recognized by
neutralizing antibodies, we aim to resolve the issue of how
the V3 loop is differentially recognized by antibodies and
how alterations in its sequence, conformation, or exposure
may affect the biological and virological properties of the
virus.
To address these questions, our laboratory and others
have carried out various structural studies of peptides with
sequences corresponding to V3 loops from different HIV-1
isolates. We have previously determined crystal structures
for neutralizing Fabs 50.1 (Rini et al., 1993), 59.1 (Ghiara et
al., 1994, 1997), and 58.2 (Stanfield et al., 1999) in complex
with V3 peptides (encompassing residues P303–P320,
KRKRIHIGPGRAFYTT) and have shown that two of the
antibodies (50.1 and 59.1) recognize one particular V3 con-
formation, while 58.2 recognizes an alternate V3 conforma-
tion that differs mainly at the extreme loop tip encompass-
ing the highly conserved GPGRAF sequence. However,
both V3 conformations contain a -strand (residues
KRKIHI) followed by a double -turn around residues
GPGRAF (Fig. 1).
A recent crystal structure has been determined for a V3
fusion protein, where V3 was inserted into the coat protein
VP1 from the rhinovirus type 14 virus and the structure of
the entire virus was determined (Ding et al., 2002). The
insert contained V3 residues IGPGRAFYTTKN, with a
three-residue linker (ADT) located at the N-terminus. In the
virus crystal structure, a type I turn exists around DTIG, a
type II turn around GRAF, and another type I turn around
TTKN, but, surprisingly, the GPG region, which is always
a -turn in complex with neutralizing Fabs, is in an ex-
tended conformation in this viral fusion protein (Fig. 1). The
V3 insert is not involved in any crystal contacts; however,
it makes many contacts with the chimeric viral protein,
possibly influencing its conformation (Ding et al., 2002).
This modified virus still binds Fabs 59.1 and 58.2, so pre-
sumably the V3 insert can adjust its conformation to con-
form to these two quite different antibody-combining sites.
In addition, NMR studies have been carried out for the
neutralizing antibody 0.5 in complex with a peptide cor-
responding to the IIIB isolate sequence (Balbach et al.,
2000; Tugarinov et al., 1999, 2000; Weliky et al., 1999; Zvi
et al., 1995, 1997, 2000), which forms a hairpin turn when
bound to the antibody (Fig. 1). Another recent NMR study
of an MN V3 peptide bound to antibody 447-52D confirms
that the peptide again forms a hairpin turn, but with a -turn
around residues GPGR (Sharon et al., 2003) (Fig. 1). A
large number of other NMR studies have indicated that V3
peptides are mostly disordered in water solution, with some
evidence for transient -turns around the GPGR region
(Catasti et al., 1995, 1996; Chandrasekhar et al., 1991; de
Lorimier et al., 1994; Dettin et al., 1993, 1997; Ghiara et al.,
1997; Gupta et al., 1993; Huang et al., 1996, 1997; Markert
et al., 1996; Sarma et al., 1997; Vranken et al., 1996; Vu et
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al., 1996, 1999; Zvi et al., 1992). NMR experiments de-
signed to confer more secondary structure on the peptides
have included adding 20% TFE (Catasti et al., 1995, 1996;
Chandrasekhar et al., 1991; Vranken et al., 1996; Zvi et al.,
1992), which usually stabilizes an -helical region C-ter-
minal to the GPGR motif (Fig. 1). Other methods that have
been used to stabilize V3 loop peptide conformation in
solution include peptide cyclization (Cabezas et al., 2000;
Chandrasekhar et al., 1991; Gupta et al., 1993; Huisman et
al., 2000; Tolman et al., 1993; Vranken et al., 1995, 1996,
2001), addition of the conformationally restricted residue
aminoisobutyric acid (Cabezas et al., 2000; Ghiara et al.,
1997), glycosylation of the peptide (Huang et al., 1996,
1997; Markert et al., 1996), attachment to resin beads (Je-
linek et al., 1997b), attachment to a bacteriophage viral coat
protein (Jelinek et al., 1997a), and attachment to other
carrier proteins, such as BPTI (Wu et al., 2000), and MUC1
(Fontenot et al., 1995). These stabilized peptides are more
ordered, with increased turn propensity in the GPGRAF
region. Interestingly, attachment of V3 peptides to the fila-
mentous bacteriophage fd viral coat protein pVIII (Jelinek
et al., 1997a) stabilizes a peptide conformation with a dou-
ble turn similar to that seen in the the crystal structure of the
Fab 59.1–peptide complex.
Antibody 83.1 is one of a group of five antibodies iso-
lated from mice by Repligen Corp. in early HIV-1 neutral-
ization studies (White-Scharf et al., 1993). These antibodies
were all raised against a 40-mer disulfide-linked peptide
containing the V3 sequence from the MN viral isolate.
While over 85,000 different hybridomas were produced in
these experiments, only 5 were chosen for further study
based on their superior neutralization properties. Some
monoclonal antibodies are very isolate-specific, while oth-
ers neutralize a broader range of viral strains, with two of
them (83.1 and 58.2) even capable of neutralizing M-tropic
isolates and field isolates passaged only one to two times
(White-Scharf et al., 1993).
Results and discussion
Despite good quality electron density maps (Fig. 2),
repeated cycles of refinement and manual rebuilding re-
sulted in slightly higher Rcryst and Rfree values (28.8%,
32.6%) than typically seen for other structures determined at
2.6 Å resolution (Rfree  25–29%) (Kleywegt and Jones,
2002). Tests for twinning (Yeates, 1997) were negative.
These slightly higher R-values appear to reflect a noncrys-
tallographic translation (x,y,z  0,0,0.45) between the two
Fab molecules in the asymmetric unit. A noncrystallo-
graphic translation of this type will result in reflections
where the index (0.45*l) is close to an integer value to be
systematically strong, whereas reflections where (0.45*l) is
close to one-half integer are systematically weak. For ex-
ample, the h,k,9 class of reflections should be strong, while
Table 1
Average I/ values as a function of l index
L l*0.45 I/I No. of reflections
0 0.00 10.3 832
1 0.45 8.6 874
2 0.90 10.0 887
3 1.35 7.8 895
4 1.80 8.1 895
5 2.25 7.7 900
6 2.70 7.8 903
7 3.15 9.7 896
8 3.60 7.3 894
9 4.05 11.4 882
10 4.50 7.3 876
11 4.95 9.9 858
12 5.40 6.0 839
13 5.85 7.3 812
14 6.30 5.4 779
15 6.75 5.9 747
16 7.20 6.2 703
17 7.65 4.7 662
18 8.10 7.4 627
19 8.55 3.8 584
20 9.00 6.3 546
21 9.45 3.4 506
22 9.90 4.8 451
23 10.35 3.2 394
24 10.80 3.2 322
25 11.25 3.1 242
26 11.70 3.0 130
Note. Where l*0.45 is approximately integer, the average reflection
intensity is higher than average. Where l*0.45 is approximately 1/2*inte-
ger, the average intensities are lower than average.
Fig. 1. Comparison of V3 peptide conformations determined by X-ray crystallography and NMR. Peptides bound to 50.1 (a) (Rini et al., 1993; Stanfield et
al., 1993) and 59.1 (b) (Ghiara et al., 1994, 1997) are very similar for the five residues in common (HIGPG) with a type II turn around GPGR. (c) The V3
insert from a V3-rhinovirus chimera (Ding et al., 2002). This structure was determined for the unliganded virus with no bound Fab. The V3 conformation
has no significant structural homology with any of the others determined to date, yet the chimeric virus will bind anti-V3 neutralizing antibodies. (d) The
peptide bound to Fab 58.2 (Stanfield et al., 1999) is similar to (a) and (b) for N-terminal residues RIHI and C-terminal residues AFY; however, the GPGR
region has a type I turn conformation. (e) An NMR structure determined for a V3 peptide in solution with 20% TFE (Vranken et al., 1995). The N-terminal
region of the peptide is highly disordered, so has not been included in this figure. This structure shows a distorted type I turn around GPGR. (f) The NMR
structure of an MN peptide bound to Fab 447-52D (Sharon et al., 2003) is similar to (a) and (b) for the N-terminal extended region KRIHI, but with a -turn
around GPGR. (g) The NMR structure of a IIIB peptide bound to Fab 0.5 (Balbach et al., 2000; Tugarinov et al., 1999, 2000; Weliky et al., 1999; Zvi et
al., 1995a, 1995b, 1997, 2000) has an unclassified turn around residues GPGR, and a QR insert prior to GPGR, characteristic of IIIB-like viruses.
Fig. 2. Stereoview of electron density for the V3 peptide bound to 83.1. The peptide electron density is from a A-weighted, 2Fo-Fc map contoured at 1.0
with the final peptide coordinates superimposed. This figure was calculated with BobScript (Esnouf, 1999) and rendered with Raster3D (Merritt and Bacon,
1997).
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the h,k,10 class of reflections should be weak (Table 1). This
atypical intensity distribution is reflected in the value for
mean E**2  1, which is expected to be 0.74 for noncen-
trosymmetric space groups with a random intensity distri-
bution (Karle et al., 1965), but is higher (0.80) than normal
for the Fab 83.1 data. Thus, the larger percentage of sys-
tematically weak data results in slightly higher than ex-
pected Rcryst and Rfree values. If reflections with F  2.0F
are removed from the calculation; Rcryst and Rfree for the
final model are 24.9 and 28.7%, respectively (4514 or
14.8% of the reflections would be rejected, if these criteria
were used).
One residue (ValL51) from each Fab molecule is located
in the disallowed region of the Ramachandran plot. This
residue is the central residue in the highly conserved, three
residue -turn which is the primary canonical structure seen
for L2 complementarity determining region (CDR) loops
(Al-Lazikani et al., 1997). Residues SerL27e and SerL28,
which are in a mobile region at the tip of L1, are in the
generously allowed region, as is SerH15, which is correctly
positioned as judged from the strong and clear electron
density at this position. SerH82b, from the second molecule
in the asymmetric unit, is also in the generously allowed
region and has clear electron density. Final statistics for the
refined structure are listed in Table 2. The two Fab mole-
cules in the asymmetric unit both have elbow angles of 133°
(Fig. 3).
With the exception of L1, the CDR loops all fall into
their expected canonical classes (Al-Lazikani et al., 1997;
Chothia and Lesk, 1987; Martin and Thornton, 1996), with
L2, L3, H1, and H2 belonging to Chothia canonical classes
1, 1, 1, and 1, respectively. The L1 CDR has a five amino
acid insertion after residue L27, and, in both Fabs in the
asymmetric unit, the tip of this loop bends away from the
antigen binding site in an unusual manner. Electron density
is weak for the tip of the loop (residues HisL27d, SerL27e,
SerL28, and GlyL29), and, as a result, SerL27e and SerL28 have
torsion angles in the generously allowed region of the Ra-
machandran plot. A comparison of this loop in 83.1 with
several CDR L1 loops of the same size (Fig. 4a) shows the
tip of the loop moves about 9 Å away from its correspond-
ing position in these other Fabs, due to crystal packing, as
the loop would otherwise clash with residues ProH41 and
GlyH42 from a symmetry-related molecule (n.b. this same
crystal contact is present for both molecules in the asym-
metric unit) (Fig. 4b). Residues H128–H135 for both mol-
ecules are disordered, as seen in other Fab structures, and
have been assigned occupancies of 0.0 in the coordinate file.
CDR H3 has a “kinked” or “bulged” base (Al-Lazikani et
al., 1997; Morea et al., 1998; Shirai et al., 1996) that would
not have been predicted from its sequence. Fab 83.1 has an
Ala at H93, an Ile at H94, and an Asp at H101 (Table 3).
Normally, if AspH101 is able to form a salt bridge with a
charged residue at H94 (Arg or Lys), then the side chain of
TrpH103 will hydrogen bond to the main-chain carbonyl
Fig. 3. The structure of the Fab 83.1–V3 peptide complex. This stereoview ribbon diagram depicts one of the two Fab molecules in the asymmetric unit, with
light and heavy chains in green and blue. All atoms of the bound V3 peptide are shown in a ball and stick representation with carbon atoms yellow, oxygen
red, and nitrogen blue. This and subsequent figures were calculated with MolScript (Kraulis, 1991) and rendered as in Fig. 2.
Fig. 4. Noncanonical L1 CDR loop from Fab 83.1. (a) Stereoview of a superposition of the VL domain from 83.1 (red) with 27 other VL domains (gray) with
the same length L1 CDR loop. The L1 CDR loop from 83.1 bends away from the canonical position by as much as 9 Å at the tip of the loop. (b) The extreme
movement of the 83.1 L1 loop (red) avoids a potential crystal packing clash with residues ProH41 and GlyH42 from a symmetry-related molecule (blue). The
canonical conformation of L1 is shown in gray.
Table 2
Summary of crystallographic data
Data collection
Wavelength (Å) 1.033
Resolution (Å) 48.2–2.57 (2.66–2.57)a
No. of observations 87,725
No. of unique reflections 29,751
Completeness (%) 96.5 (80.0)
Rsym (%)b 11.5 (39.4)
Average I/ 9.4 (2.1)
Refinement statistics all refl.  0.0 F All refl.  2.0 Fc
Resolution (Å) 48.2–2.57 (2.66–2.57)
Total no. of reflections 29,740 25,226
No. in test set 1469 1238
Rcryst (%)d 28.8 (46.4) 24.9 (30.0)
Rfree(%)e 32.6 (52.5) 28.7 (35.9)
No. of Fab atoms 6615
No. of peptide atoms 156
No. of waters 107
Average B values (Å2)
Fab variable domain 1 26.9
Fab constant domain 1 30.5
Fab variable domain 2 28.4
Fab constant domain 2 32.3
Peptide 1 41.1
Peptide 2 37.4
Waters 19.6
Ramachandran plot (%)
Most favored 86.9
Additionally allowed 11.9
Generously allowed 0.9
Disallowed 0.3
r.m.s. deviations
Bond lengths (Å) 0.007
Angles (°) 1.6
Dihedral (°) 26.9
Improper (°) 0.98
a Numbers in parentheses are for the highest resolution shell of data.
b Rsym  ¥hkl

I  I/¥hld

I
c All data, including negative intensities, were used throughout the
refinement; these values were calculated for the final model only.
d Rcryst  ¥hkl

F0  Fc/¥hkl

F0
e Rfree is the same as Rcryst but for 5% of the data excluded from the
refinement.
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Fig. 5. Stereoview of H3 loop conformations from Fabs 83.1 (top), B02C11 (middle), and 26-10 (bottom). Each of these H3 loops has a “bulged” or “kinked”
torso, rather than the predicted extended torso, with AspH101 unexpectedly not interacting with the indole nitrogen from Trp H103.
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oxygen of the residue three positions upstream, resulting in
a kinked base. 83.1 has no charged side chain at position
H94 to interact with AspH101, and, surprisingly, the only
interaction made by the AspH101 side chain is a single
hydrogen bond to a water molecule. AspH101 is close (6
Å) to the positively charged N-terminus of the peptide
ligand (LysP305, ArgP306), but makes no direct interactions
with the peptide in the crystal structure. At least two other
Fabs have kinked H3 bases not predicted by their sequence,
Fab 26-10 (1IGJ) (Jeffrey et al., 1993) with AlaH93, GlyH94,
and AspH101, and Fab B02C11 (1IQD) (Spiegel et al., 2001)
with AlaH93, ValH94, and AspH101 (Fig. 5). In the 26-10
structure, AspH101 is stabilized by a hydrogen bond to
TyrH27 OH, and in the B02C11 structure, AspH101 makes
two hydrogen bonds to the main-chain amide nitrogens of
AspH96 and AlaH99.
Clear electron density is present for 10 residues of the
16-mer bound V3 peptide, allowing the structure of residues
P305–P316 (KRIHIGPGRA) to be interpreted from the
maps (Fig. 2). Additional weak electron density is seen at
either end of this 10-mer peptide, but has not been modeled
due to difficulty in its interpretation. Residues at the N-
terminus (KRIHIG) are in an extended conformation, fol-
lowed by a type I turn around residues GPGR and the start
of a type II turn around GRA. The peptide forms a double
turn, very similar in shape to that seen in both the Fab
59.1-peptide (Ghiara et al., 1994, 1997) and the Fab 50.1-
peptide structures (Fig. 6). Differences in main-chain tor-
sion angles arise compared to the 59.1 peptide, due to
different locations of the carbonyl oxygens of P309, P313,
and P315 in the 83.1 or 59.1 structures; nevertheless, the
overall shape of the peptide remains the same. Although the
medium resolution data of these structures (2.8 and 3.0 Å
for 59.1, and 2.57 Å for 83.1) can sometimes make the exact
positioning of carbonyl oxygens problematic, repeated in-
spections of the 83.1 and 59.1 electron density maps indi-
cate that the carbonyl oxygens are correctly positioned. The
83.1 peptide also differs slightly from the 50.1 and 59.1
peptides in the relative disposition of the extended region
Fig. 6. Comparison of the V3 peptide conformations from complexes with Fabs 50.1 (pink), 59.1 (gray), 83.1 (green), and 58.2 (blue). The peptides have
all been superimposed onto the V3 loop peptide from 50.1, and their overlapped C traces are shown at the bottom right. The 83.1 peptide has a very similar
shape to the 50.1 and 59.1 peptides for both its extended region (KRIHIG) and its crown (GPGRA); however, a slight difference is seen in the disposition
of these two segments. The superposition for 83.1 was carried out using the crown residues.
Fig. 7. The antibody combining site of Fab 83.1. Stereoview of the Fab binding site and its interactions with the V3 peptide. Contacting residues were
identified with Contacsym (Sheriff et al., 1987a). The peptide residues are labeled in black; the light chain residues are labeled in red, and the heavy chain
residues are labeled in blue. The molecular surface for the Fab was calculated with GRASP (Nicholls et al., 1991) and is colored according to the electrostatic
potential (blue  positive, red  negative, surface potential from 15 to 15 kT).
Table 3
Sequences of the anti-V3 Fabs 83.1, 59.1 (Ghiara et al., 1994, 1997), 50.1 (Rini et al., 1993), and 58.2 (Stanfield et al., 1999)
(a) Light chains
10 20 abcde 30 40 50
83.1 DVVMTQSPVSLPVSLGDQASISCRSSQSLGHSSGNTYLHWFLQKPGQSPKLLIYKVSNRFS
59.1 DIVMTQSPASLVVSLGQRATISCRASESVDS-YGKSFMHWYQQKPGQPPKVLIYIASNLES
50.1 DIVLTQSPGSLAVSLGQRATISCRASESVDD-DGNSFLHWYQQKPGQPPKLLIYRSSNLIS
58.2 DIVLTQSPASLAVSLGQRATISCKASQGVDF-DGASFMNWYQQKPGQPPKLLIFAASTLKS
CDR 1 CDR 2
60 70 80 90 100
83.1 GVPDRFSGSGSGTDFTFKISRVEAEDLGVYFCFQTTHDPYTFGGGTKLEI
59.1 GVPARFSGSGSRTDFTLTIDPVEADDAATYYCQQNNEDPPTFGAGTKLEM
50.1 GIPDRFSGSGSRTDFTLTINPVEADDVATYYCQQSNEDPLTFGAGTKLEI
58.2 GIPARFSGRGSGTDFTLNIHPVEEEDAATYYCQQSHEDPLTFGAGTKLEL
CDR 3
(b) Heavy chains
10 20 30 ab 40 50 60
83.1 EVQLQESGPSLVKPSQTLSLTCSVTGVSITSGYWN--WIRKFPGNKFEYMGYISKSGSAYYN
59.1 QVKLQESGPAVIKPSQSLSLTCIVSGFSITRTNYCWHWIRQAPGKGLEWMGRICYEGSIYYS
50.1 QVQLQESGPGILQPSQTLSLTCSFSGFSLSTYGMGVSWIRQPSGKGLEWLAHIFWDGDKRYN
58.2 DVQLQQSGPDLVKPSQSLSLTCTVTGYSITSGYSWH-WIRQFPGNKLEWMGYIHYSAGTNYN
CDR 1 CDR 2
70 80 abc 90 100abcdefghi 110
83.1 PSLKSRISFTRDTSKNQFYLKLNSVTTEDTATYYCAIDDF––––––––––––DIWGAGTTVTVSS
59.1 PSIKSRSTISRDTSLNKFFIQLISVTNEDTAMYYCSRKNHMYETYF––––––DVWGQGTTVTVSS
50.1 PSLKSRLKISKDTSNNQVFLKITSVDTADTATYYCVQEGY––––––––––––IYWGQGTSVTVSS
58.2 PSLKSRISITRDTSKNQFFLQLNSVTTEDTATYYCAREEAMPYGNQAYYYAMDCWGQGTTVTVSS
CDR 3
Note. CDR residues are shown in bold. CDR definitions and numbering according to standard conventions (Kabat et al., 1991).
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(P305–P312) versus the double turn region (P312–P316),
by an angle of about 60° (Fig. 6).
The peptide makes contact with both the light and the
heavy chains from the Fab, with 110 (107) total contacts for
molecule 1 (molecule 2) (Fig. 7). Of these contacts, 7 (8) are
hydrogen bonds, with no charge-charge interactions (Table
4). Six (7) hydrogen bonds are to peptide main-chain atoms,
with 1 (1) bond to the ArgP315 side chain. The H3 CDR
makes the most contacts (39%, 37%), followed by H1 (20%,
15%), L1 (10%, 12%), L2 (4%, 4%), L3 (9.1%, 14.0%), H2
(7%, 6%), light-chain framework residues (10%), and
heavy-chain framework residues (1%). The peptide buries
478 (479) Å2, while the Fab buries 490 (549) Å2 of molec-
ular surface, with about 50 (59)% of the total from the heavy
chain.
The 83.1-peptide structure is the fourth crystal structure
determined for a neutralizing antibody–V3 peptide com-
plex. Analysis of the conformations of the four peptides
reveals that three of the peptides share very similar confor-
mations (Fig. 6), while that of the fourth (58.2) differs
around the residues at the tip of V3 (GPGR). The four
antipeptide antibodies (83.1, 50.1, 59.1, 58.2) were all gen-
erated during the same set of experiments from related mice,
and the peptides used for immunization and for cocrystal-
lization all correspond to the MN viral isolate sequence.
However, the antibodies themselves do not have strong
sequence (Table 3) or structural homology (Fig. 8), and in
fact, have CDR loops of various size, shape, and sequence
composition. Thus, the similarity among conformation of
the three peptides bound to 50.1, 59.1, and 83.1 is not
because the Fabs themselves are highly similar. In fact, the
peptides, although adopting the same shapes, bind in dif-
ferent orientations and locations in the antibody-combining
site (Fig. 8). Because the antibodies were chosen for their
ability to neutralize, and, hence, to bind to intact virus, these
Table 4
Hydrogen bonding distances between Fab and peptide
Fab atom Peptide atom distance (Å)
mol1 mol2
AspH96 O2 IleP307 N 3.68 3.31
LysL50 N HisP308 O 3.12 2.96
AspH96 O2 HisP308 N 3.23 3.20
ThrL91 O1 IleP309 O 3.30 2.93
AspH96 O1 IleP309 N 2.71 2.71
AspH96 O1 GlyP312 N 2.83 2.82
AspH95 O1 GlyP314 N 3.01 3.22
ThrL91 O ArgP315 NH2 2.66 2.69
Note. Hydrogen bonds calculated with HBPLUS (McDonald and Thorn-
ton, 1994).
Fig. 8. Antigen binding sites of Fabs 83.1, 59.1, 58.2, and 50.1. These four Fabs have only limited sequence homology in their variable domains, reflected
in their binding sites for the V3 loop, which are shaped and oriented differently in each Fab; nevertheless, the striking similarity in peptide conformation
persists despite very different antigen binding sites. Residues GPGR are shown in red, with their side chains also represented, while the backbone of the
remainder of the peptide is shown in blue. Molecular surfaces calculated with GRASP (Nicholls et al., 1991).
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peptide conformations should reflect highly populated or
energetically preferred conformations of the V3 loop on the
intact virus. If V3 were totally disordered and had no stable
structure, it is unlikely that three different neutralizing an-
tibodies would recognize such similar peptide conforma-
tions. Thus, the V3 loop structures that we have identified
would appear to represent a recurring and highly populated
conformer on the intact virus, suggesting that the different
peptide conformation observed when bound to Fab 58.2
may also be conformationally accessible on the intact virus.
These X-ray crystallographic “snapshots” of V3 peptides
in complex with neutralizing antibodies help define the
range of conformations that V3 can adopt. As most studies
suggest that V3 interacts with coreceptors CCR5 and
CXCR4 during viral cell entry, this structural information
may be useful in the design of V3-based fusion inhibitors.
Ultimately, a better understanding of the quaternary struc-
ture of intact gp120/gp41 oligomers as they exist on the
viral surface, and of the role of V3 in this complex protein
assembly, is essential for truly understanding how HIV-1
carries out its receptor binding and viral fusion activities.
Materials and methods
Fab purification and crystallization
MAb 83.1 (IgG1,) was generated by immunization
of ASW mice with cyclic peptide RP70 (INC*TRPN-
YNKRKRIHIGPGRAFYTTKNIIGTIRQAHC*NIS with
a disulfide bond between the two C* residues) corre-
sponding to the MN sequence (White-Scharf et al., 1993).
The antibody was produced in ascites fluid of BALB/c
mice and purified with an immobilized protein A column.
Fab fragments were produced from immunoglobulin by
cleavage with 3% pepsin for 2 h at 37°C, reduction with
15 mM cysteine for 3 h at 37°C, followed by purification
on a protein A and then a protein G column (Smith,
1993). Fab was concentrated to 15.0 mg/ml for crystal-
lization studies.
Fab was mixed with linear 16-mer peptide MP1 (CKRI-
HIGPGRAFYTTC) in a 6:1 (peptide:Fab) molar ratio.
Crystals were grown using the sitting-drop vapor diffusion
method with a reservoir solution (1 ml) of 1.6 M Na/K
phosphate, 5% isopropanol, pH 6.0. One microliter of Fab/
peptide complex was mixed with an equal volume of the
reservoir solution. The crystals grow as clusters of thin
plates. Crystals were usually observed after 3 days; how-
ever, the crystal used for data collection grew over a 2-week
period, was slightly thicker than typically seen, and grew
singly with no satellite crystals attached.
Data collection
As the 83.1-peptide crystals suffer from significant radi-
ation-induced decay, even when cryocooled to liquid nitro-
gen temperatures, efforts were taken to collect the data as
rapidly as possible. Data were collected from a single crys-
tal at the Advanced Photon Source, beamline 19-ID, at
100K, using a wavelength of 1.033 Å and a step size of 0.5°
with a CCD detector. The crystals were cryoprotected by a
quick plunge into a solution containing 25% glycerol, 1.6 M
Na/K phosphate, 5% isopropanol, pH 6.0. The data were
reduced in monoclinic space group P21 with unit cell di-
mensions a  60.5 Å, b  122.6 Å, c  69.5 Å, and  
108.5° and a refined mosaicity of 0.8°. Data were indexed,
integrated, and scaled using HKL2000 (Otwinowski and
Minor, 1997) using all observations greater than 3.0.
Data collection statistics are outlined in Table 2.
Structure determination
The Matthews coefficient (Vm) (Matthews, 1985) was
estimated as 2.6 Å3/D based on two Fab molecules in the
asymmetric unit (53% solvent). The native Patterson map
showed an unexpected peak at u, v, w  0.0, 0.0, 0.45 with
a peak height of 37 (the origin peak height was 150)
indicative of a noncrystallographic translation between the
two Fab molecules in the asymmetric unit of approximately
0, 0, 1/2. Rotation functions were carried out using the
Crowther fast rotation function (Crowther and Blow, 1967),
as implemented in MERLOT (Fitzgerald, 1988), against our
database of 125 intact Fab models. Strong rotation function
solutions were found for models with elbow angles of ap-
proximately 135°, with Fab 59.1 (1ACY) (Ghiara et al.,
1994) providing the best solution. A model was then con-
structed from the constant region (CH1, CL) of Fab 58.2
(from unpublished coordinates refined to 1.6 Å resolution,
and with the appropriate sequence for an IgG1, ) (Stanfield
et al., 1999), the VL domain of an anti-Dansyl antibody
(1DLF) (Nakasako et al., 1999) (88% sequence identity),
and the VH domain of HyHEL-63 (1DQQ) (Li et al., 2000)
(84% sequence identity) assembled with an elbow angle of
135° by superposition over the corresponding domains of
Fab 59.1 (1ACY). The EPMR (Kissinger et al., 1999) pro-
gram was then used to correctly position this model in the
cell, followed by positional refinement using four individual
domains (the variable and constant regions from each mol-
ecule in the asymmetric unit). EPMR located the first Fab
molecule in the asymmetric unit with a correlation coeffi-
cient of 28.7% and an R-value of 55.8%, and, subsequently,
the second Fab molecule (holding the first molecule fixed)
with a correlation coefficient of 50.8% and an R-value of
46.8%.
Model building and refinement
The hybrid model was mutated to the correct sequence
for 83.1, rebuilt using TOM/FRODO (Jones, 1982), and
refined with CNS version 1.1 (Bru¨nger et al., 1998) with an
overall, anisotropic B-value correction and bulk solvent
correction. All refinement and model building were carried
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out using all measured data (F  0.0F), with tight NCS
restraints early on in the refinement, which were released
gradually toward the end of refinement. Electron density
maps for model building included A-weighted (Read,
1986) 2F0  Fc, F0  Fc and composite annealed omit 2F0
 Fc maps, as well as solvent flippped/NCS-averaged 2F0
 Fc maps, all calculated with CNS (Bru¨nger et al., 1998).
An Rfree test set consisting of 5% of the reflections was
maintained throughout the refinement.
Structure analysis
The Fab molecules are numbered according to the Kabat
convention (Kabat et al., 1991) with light and heavy chains
labeled “L” and “H.” The peptide is labeled “P” and is
numbered according to the HXB2 isolate sequence (KRI-
HIGPGRA; 305–309, 312–316). Buried molecular surface
areas were calculated with the program MS (Connolly,
1993) with a 1.7 Å probe radius and standard van der Waals
radii (Gelin and Karplus, 1979). Hydrogen bonds were
evaluated using the program HBPLUS (McDonald and
Thornton, 1994) and van der Waals contacts were assigned
with the program Contacsym (Sheriff et al., 1987a, 1987b).
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